JP2001206900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001206900A5 JP2001206900A5 JP2000015781A JP2000015781A JP2001206900A5 JP 2001206900 A5 JP2001206900 A5 JP 2001206900A5 JP 2000015781 A JP2000015781 A JP 2000015781A JP 2000015781 A JP2000015781 A JP 2000015781A JP 2001206900 A5 JP2001206900 A5 JP 2001206900A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- compound
- antigen
- fragment
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 5
- SBXWFLISHPUINY-UHFFFAOYSA-N triphenyltin Chemical compound C1=CC=CC=C1[Sn](C=1C=CC=CC=1)C1=CC=CC=C1 SBXWFLISHPUINY-UHFFFAOYSA-N 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000000984 immunochemical effect Effects 0.000 description 3
- 0 C*(C(O)=O)[Sn](c1ccccc1)(c1ccccc1)c1ccccc1 Chemical compound C*(C(O)=O)[Sn](c1ccccc1)(c1ccccc1)c1ccccc1 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910020923 Sn-O Inorganic materials 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- -1 triphenyltin compound Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000015781A JP2001206900A (ja) | 2000-01-25 | 2000-01-25 | トリフェニルスズ化合物の抗体及び測定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000015781A JP2001206900A (ja) | 2000-01-25 | 2000-01-25 | トリフェニルスズ化合物の抗体及び測定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001206900A JP2001206900A (ja) | 2001-07-31 |
| JP2001206900A5 true JP2001206900A5 (enExample) | 2007-03-22 |
Family
ID=18543023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000015781A Withdrawn JP2001206900A (ja) | 2000-01-25 | 2000-01-25 | トリフェニルスズ化合物の抗体及び測定方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001206900A (enExample) |
-
2000
- 2000-01-25 JP JP2000015781A patent/JP2001206900A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5772998A (en) | Monoclonal antibodies to transforming growth factor-beta and methods of use | |
| Lindstrom et al. | Specificities of antibodies to acetylcholine receptors | |
| JP3392860B2 (ja) | スフィンゴ糖脂質に対する免疫応答を誘導する抗イディオタイプ抗体及びその使用 | |
| NZ611387A (en) | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment | |
| JP2001519402A5 (enExample) | ||
| CN1096516A (zh) | 改进的脑膜炎双球菌多糖结合菌苗 | |
| JP2003525061A5 (enExample) | ||
| CN87105716A (zh) | 利用不溶性免疫复合物提高抗体的生产 | |
| JP2002504994A (ja) | 抗アロタイプモノクローナル抗体を使用するイムノアッセイ | |
| CA1340311C (en) | Screening for antibodies which bind carbohydrate epitopes of tumor-associated antigens, and uses thereof | |
| JP3884586B2 (ja) | イミダクロプリドのハプテン化合物、抗体及び測定方法 | |
| WO1987001941A1 (en) | Composition containing toxin linked to an antigen non-specific antibody | |
| JP2001206900A5 (enExample) | ||
| JPH06505714A (ja) | コレステロール過剰血症およびアテローム動脈硬化を防止するためのコレステロールに対するワクチン | |
| Fernandez et al. | Immune responses to bacterial polysaccharides: terminal epitopes are more immunogenic than internal structures | |
| JP2000095769A5 (enExample) | ||
| JP2025015580A5 (enExample) | ||
| HU204897B (en) | Process for producing monoclonal antibodies capable of recognizing n-acetylneuraminic acid of beta-configuration, as well as hybridomas producing same | |
| JP2000281645A5 (enExample) | ||
| WO2009108307A2 (en) | Diagnostic uses of anti-h8 monoclonal antibodies | |
| Baxter et al. | Specificity enhancement of polyclonal antisera by the induction of tolerance to unwanted cross‐reacting determinants | |
| Schroer et al. | Functional, structural, and antigenic similarities of guinea pig anti-phosphorylcholine antibodies | |
| EP0568500A1 (en) | Anti-idiotype monoclonal antibodies directed against anti-TNF antibodies | |
| Wellerson et al. | Enhanced binding activity observed between anti-carcinoembryonic monoclonal antibodies | |
| JP3123056B2 (ja) | 合成糖脂質特異性モノクローナル抗体 |